Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ndidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A)
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ... preventive vaccines against cancers and infectious diseases, announced today ... in its Phase I clinical study of VGX-3400X, a ... influenza delivered using intramuscular (IM) electroporation. These results were ...
... Vapotherm, a privately held manufacturer of respiratory care devices ... received approval from the Medical Device Bureau of Health Canada ... later this year in the Canadian hospital market. The device ... "We are pleased to receive our license in ...
Cached Medicine Technology:Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox 2
(Date:7/12/2014)... July 12, 2014 Ladies, it doesn't matter ... there. Those who are looking for an affordable gown can ... special occasion dresses) to get their dream items. Recently, the ... tea length gowns . Along with that, it is also ... enjoy the special offer; the deadline of this promotion is ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Reducing the ... incidence of Lyme disease and other tick-borne infections ... that deer populations can be manipulated to reduce human ... of contracting Lyme disease," the researchers wrote. White-tailed ... which transmit Lyme disease to people. The study ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
Breaking Medicine News(10 mins):Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... earthbound "angels" who have,brightened the lives of Michigan children ... The Caring for Children Angel Awards recognize good ... awards have been,sponsored annually by the Michigan Blues since ... a Friday, Nov. 9 reception and awards,program at the ...
... to remove,some fat (cellulite) and also tighten your skin ... Plastic Surgery and Laser Center in Farmington Hills,offers a ... goals -- without surgery. What,s more they can ... Farmington Hills plastic surgeon and,owner of the Center, said ...
... (NMA) announced the appointment of Byron Sogie-Thomas, M.S., ... Policy, Mr. Sogie-Thomas,will be responsible for advising the ... current policy issues. He will also assume overall,responsibility ... federal law,regulation, and policy. "Byron,s knowledge of ...
... Pharmacists Association (NCPA) is pleased today to announce ... public affairs., "We,re pleased to have such ... team," said Bruce Roberts, RPh, NCPA Executive Vice,President ... and,Administration experience will undoubtedly increase our organization,s,volume as ...
... for Hospital Quality,Improvement, BALTIMORE, Oct. 11 ... the mid-Atlantic region were,recently honored with a ... America. CareFirst BlueCross BlueShield (CareFirst) received,the 2007 ... 100,000 Lives and,Beyond Collaborative. CareFirst and the ...
... by diabetes to enter global,contest supporting children in developing nations and ... ... 11 "American Idol" finalist and,rising Hickory Records recording artist Elliott ... the Inspired by Diabetes global,campaign to support the care of children ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3Health News:Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat 2Health News:National Medical Association Selects New Director of Health Policy 2Health News:Lisa Camooso Miller Joins National Community Pharmacists as Vice President of Public Affairs 2Health News:National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 3Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 4Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 5
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: